Latest Earnings

Stock Analysis

Stock Movers

Deals

Gainers And Losers

Equities

IPOs

Artificial Intelligence

Technology

Web Stories

Benzinga Inspire

Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.

Top NSE, BSE, Sensex Moving Share Market News: Gainers, Losers, Trading Ideas

acf/news-featured-section

HAL-GE Fighter Jet

Hindustan Aeronautics jumped 4% higher at the bourses on Monday following the company&#8217;s second-quarter results where the firm&#8217;s net profit was seen jumping by 22%.



What Happened: The aerospace and defence company&#8217;s <a href="https://in.benzinga.com/news/earnings/24/11/41963672/hal-q2-net-profit-jumps-22-to-1-510-cr-beats-estimates">net profit for the quarter</a> under review stood at ₹1,510.4 crore, ahead of the street&#8217;s estimates. Revenue from operations came in at ₹5,976.29 crore, a 6% increase&nbsp;year-on-year, below the analysts&#8217; estimates.



CLSA has an &#8220;outperform&#8221; rating on HAL with a target price of ₹4,731. Despite delays in Russian aircraft and helicopter orders, HAL&#8217;s order pipeline for the next decade remains strong at $45 billion (₹3.8 lakh crore), it said. 



The brokerage sees an expected order of large helicopters and Sukhoi aircraft in the second half of FY25, along with visibility on the GE engine deal as the major catalysts in the firm&#8217;s growth.



See Also: <a href="https://in.benzinga.com/markets/equities/24/11/42028604/ev-prices-may-not-drop-further-due-to-stabilising-battery-costs-says-tata-motors-md">EV Prices May Not Drop Further Due To Stabilising Battery Costs, Says Tata Motors MD</a>



Jefferies has a &#8220;buy&#8221; rating on HAL with a target price of ₹5,500. In Q2 FY25, the company saw a 7% YoY increase in EBITDA, with margins improving by 37 basis points to 27.5%. 



The higher-margin service income likely played a key role in the performance, especially given delays in aircraft deliveries due to engine supply issues with its partnership with GE, the brokerage said.



Antique Broking also maintained its &#8220;buy&#8221; rating for the stock with a target price of ₹5,902. Antique Broking expressed confidence in HAL&#8217;s long-term business prospects and execution capabilities. The brokerage estimates that HAL is on track to achieve a 15% compound annual growth rate (CAGR) in revenue over FY24–27E.



With the potential for multi-year double-digit earnings growth and a robust return ratio profile exceeding 20%, analysts at Anrique believe the stock offers an attractive valuation at current levels.



Price Action: Shares of HAL rose 2.62% to trade at ₹4,194.05 on Monday morning. The stock jumped 4% to hit an intraday high of ₹4,248.



Read Next: <a href="https://in.benzinga.com/markets/equities/24/11/42023014/nbcc-sees-orderbook-expand-to-84-400-cr-in-q2">NBCC Sees Orderbook Expand To ₹84,400 Cr In Q2</a>

Earnings

News

Price Target

Reiteration

Markets

Analyst Ratings

Movers

Trading Ideas

The brokerage sees an expected order of large helicopter and Sukhoi aircraft as in the second half of FY25, along with visibility on the GE engine deal as the major catalysts in the firm's growth.

HAL Shares Jump 4% As Brokerages Remain Strongly Bullish After Q2-Print 

Nivedita Hazra

The brokerage sees an expected order of large helicopter and Sukhoi aircraft as  in the second half of FY25, along with visibility on the GE engine deal as the major catalysts in the firm's growth.

HAL Shares Jump 4% As Brokerages Remain Strongly Bullish After Q2-Print

Stock market analysts

NBCC&#8216;s share price has remained under pressure ever since the company posted its earnings for the quarter ended September. However, analysts at Nuvama think the stock can bounce back.



The NBCC Analyst: Analysts at Nuvama upgraded the stock&#8217;s rating to &#8220;buy&#8221; from &#8220;hold&#8221; with a price target of ₹133. The target indicates an around 47% upside from the stock&#8217;s last closing price of ₹89.90.



The NBCC Thesis: Improved order intake, execution, and margins, coupled with progress in real estate monetization, are seen as positives by the analysts. The brokerage added that following the recent correction in the stock, it is upgrading the PSU&#8217;s rating.



Nuvama highlighted that NBCC&#8217;s revenue for the September quarter grew 19% year-on-year (YoY) and 15% sequentially to around ₹2,460 crore. However, the brokerage noted that the EBITDA margin declined by around 60 basis points YoY and 20 basis points quarter-on-quarter (QoQ) to 4.1%, <a href="https://in.benzinga.com/news/earnings/24/11/41932498/nbcc-q2-net-profit-jumps-53-to-122-cr">which weighed on the adjusted profit after tax (PAT). </a>



The company has guided for a revenue of ₹13,000 crore in FY25, up from ₹10,400 crore in FY24. The construction major expects EBITDA margins to improve to 5.5–6% (from 4.9% in FY24) and PAT margins to rise to 6–7%. The brokerage added that NBCC is also targeting a 20% YoY revenue growth in FY26.



See Also: <a href="https://in.benzinga.com/markets/equities/24/11/42022982/garden-reach-shipbuilders-reports-4-dip-in-orderbook-at-24-221-cr-in-q2">Garden Reach Shipbuilders Reports 4% Dip In Orderbook At ₹24,221 Cr In Q2</a>



The brokerage also mentioned the company&#8217;s strong order. NBCC&#8217;s consolidated o<a href="https://in.benzinga.com/markets/equities/24/11/42023014/nbcc-sees-orderbook-expand-to-84-400-cr-in-q2">rder book grew QoQ to ₹84,400 crore in the September quarter, compared to ₹81,000 crore in the previous quarter. </a>



Of this, around ₹22,000 crore worth of projects are currently under execution. The company awarded contracts worth ₹3,600 during Q2FY25 and ₹7,300 crore in the first half of FY25, with plans to award ₹14,000 crore–15,000 crore worth of projects for the entire fiscal year, the brokerage noted.



While the company&#8217;s book-to-bill ratio stands at a robust 7.6x, around 45% of its order book comprises self-revenue-generating projects, where the pace of real estate monetization will play a critical role, according to Nuvama.



The brokerage noted that NBCC has fully sold its World Trade Center project and plans a bulk sale for the Sarojini Nagar project once the occupancy certificate is received. In the Amrapali project, the company has sold inventory worth ₹3,650 billion so far.



Price Action: NBCC&#8217;s share price was up 0.22% to trade at ₹89.80 on Monday morning.



Read Next: <a href="https://in.benzinga.com/analyst-ratings/analyst-color/24/11/42022693/clsa-reverses-course-increases-allocation-to-indian-equities-while-cutting-back-on-">CLSA Reverses Course, Increases Allocation To Indian Equities While Cutting Back On China</a>



Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Analyst Color

Upgrades

NBCC's share price has remained under pressure ever since the company posted its earnings for the quarter ended September. However, analysts at Nuvama think the stock can bounce back.

NBCC Shares Remain Under Pressure After Q2, But Analyst Sees Over 45% Upside Ahead 

Benzinga India Staff

NBCC

NBCC Shares Remain Under Pressure After Q2, But Analyst Sees Over 45% Upside Ahead

SPlendor

Hero Motocorp shares were on the rise on Monday after the company posted its results on Thursday last week that beat street estimates.



What Happened: The two-wheeler maker <a href="https://in.benzinga.com/news/earnings/24/11/41977061/hero-motocorp-q2-net-profit-jumps-14-to-1-203-54-cr-beats-estimates">posted a net profit of ₹1,203.54 crore</a>, making a 14% year-on-year increase. The company that manufactures Harley Davidson in India reported an 11% jump in revenue in operations to ₹10,463 crore in the quarter, beating analyst estimates. 



The company sold 15.20 lakh units in the quarter compared to 14.16 lakh units in the previous year. Niranjan Gupta, CEO of Hero Motocorp said that the company will release three models Xpulse 210, Xtreme 250R and Karizma XMR 250 in the Entry and Deluxe segment in the next 6 months.



Brokerage Views: Jefferies gave a "buy" call with a target price of ₹5,500. The brokerage said that Q2 results were in line. EBITDA per vehicle rose to a new high in the quarter, said the research firm. According to Jefferies, the Indian two-wheeler market is poised for strong double-digit growth in the next 3 years. 



See Also: <a href="https://in.benzinga.com/markets/equities/24/11/42028604/ev-prices-may-not-drop-further-due-to-stabilising-battery-costs-says-tata-motors-md">EV Prices May Not Drop Further Due To Stabilising Battery Costs, Says Tata Motors MD</a>



However, the research firm noted that the company's decline in the 2-wheeler market share is a concern and adverse demand profile shifts are a concern. Any success of the company in the premium and EV segment will be positive. 



Nomura also kept a "buy" call with a target price of ₹5,805. The brokerage said that rural improvement is a key catalyst. Despite the company posting healthy earnings growth and attractive valuation, the margins have room to improve, the research firm said. The brokerage also expects the two-wheeler market to grow by 10% over FY25-26 due to rebalancing of growth and positive monsoons.&nbsp;



The brokerage firm noted that there are early signs of rural pick up which will support sales as the rural mix makes up 54% of the sales. The research firm said that the company's margins will improve as EV drag reduces due to new models and PLI benefits. 



Price Action: Shares of Hero Motocorp rose 3.41% to ₹4,760.90 on Monday morning. 



Read Next: <a href="https://in.benzinga.com/markets/equities/24/11/42023014/nbcc-sees-orderbook-expand-to-84-400-cr-in-q2">NBCC Sees Orderbook Expand To ₹84,400 Cr In Q2</a>

Hero Motocorp shares rise 3.41% after posting a net profit of ₹1,203.54 crore in Q2, with 11% jump in revenue. Rural improvement expected to boost sales.

Hero MotoCorp Shares Jump 3% After Strong Q2 Results 

Ananthu C U

Hero Motocorp

Hero MotoCorp Shares Jump 3% After Strong Q2 Results

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Monday, citing orforglipron data, which strengthens <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">the case for obesity dominance</a>.



Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">diet and exercise alone</a>.



In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">using the efficacy estimand</a>.



After a choppy second half of 2024, &#8220;Lilly is off to a solid start in &#8217;25,&#8221; Cantor analyst Carter Gould writes. The company reported positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics. 



Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a>



&#8220;&#8230;We view the ACHIEVE-1 data as meaningfully de-risking a 13-16% weight loss profile, and if safety/tolerability holds up, it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,&#8221; analyst Gould adds.



Cantor writes that Eli Lilly could have an over 85% share of the obesity market by 2029-2030E when the next wave of entrants hits. Cantor initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price target of $975</a>.



Eli Lilly&#8217;s first-quarter earnings are in the front row for investors.



The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $12.93 billion</a>.



Cantor expects modest beats across Mounjaro/Zepbound and that the company will likely reaffirm the FY25 topline guide ($59-61 billion) as a raise is more likely after the second quarter of 2025.



In March, the company announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">obese people by 2050</a>.



Rival&nbsp;Novo Nordisk A/S&#8217;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is feeling the pressure as it tries to move up the launch of Wegovy in India to better compete with Lilly.



BofA Securities has also made minor changes to its model for Eli Lilly ahead of Q1 earnings.



BofA analyst Tim Anderson writes that IQVIA recently began including Lilly Direct vials in its TRx (total prescription) data. As for pricing, Eli Lilly expects an overall price decline by the mid-to-high single digits in 2025. While this isn&#8217;t specific to any product, the company suggests that falling prices for its obesity drugs will likely be a major factor.



For 2025/2026, revenues are changed by +1%/+0.4%, and EPS estimates change by +1.9%/-0.7%. No substantial changes to Mounjaro/Zepbound forecasts.



BofA reiterates the Buy rating with a price target of $1,000. &#8220;We continue to like LLY, not &#8220;expensive&#8221; on a PE-to-growth basis, by our math.&#8221;



Price Action: LLY stock is up 0.59% at $822.84 at the last check Tuesday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026" target="_blank" rel="noreferrer noopener">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></li>
</ul>



Image: Shutterstock

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

On 4/20, while most were lighting up, Snoop Dogg dropped a trip—visually speaking.



Directed by Dave Meyers and produced by Psyop in collaboration with Temple Caché, the music video for &#8220;Last Dance with Mary Jane&#8220;—Snoop's cannabis-laced reimagining of the Tom Petty classic—takes viewers on a mind-bending ride through the rapper's life, inner cities and stoner dreams. The track, from Snoop's &#8220;Missionary&#8221; album, released last year via Death Row, Aftermath and Interscope, features Jelly Roll, cameos by B-Real, Method Man, Redman, Wiz Khalifa and even visual nods to Bob Marley, Tupac and Tom Petty himself.



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Last Dance with Mary Jane ft. Tom Petty &amp; Jelly Roll (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/rseqmSGH7xk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div></figure>



This isn't your typical hip-hop video; it's a genre-smashing blend of handcrafted animation and generative AI, layered across a semi-autobiographical storyline about Snoop's lifelong relationship with cannabis and the justice issues it invokes.



"Being able to partner with Dre, Snoop and Dave to create a visual style that hasn't been done is exactly the type of project we live for," said Joe Maggiore of Psyop.



The visuals? Insane. Think 2D, 3D, collage, motion design and surreal AI landscapes. But it's not AI doing the storytelling—every frame was touched by human hands, ensuring emotional nuance and a narrative throughline. "Storytelling requires nuance," said Psyop's Andrew Linsk, explaining why AI alone couldn't carry the vision.



The end result is both a love letter to cannabis and a statement on America—its cities, its culture, its contradictions.



<h2 class="wp-block-heading">Meanwhile… Jet Black Roses Go Full Funkadelic</h2>



If Snoop's video is a lucid dream, Jet Black Roses' new single is a fever-drenched backyard boogie. Its latest track, &#8220;Psychoboogie Hoochiecoo,&#8221; arrives with a brain-melting video by Steffan Heil (of Adult Swim fame) and production by Greg Archilla (Neil Young, Collective Soul, Matchbox Twenty).



No AI. No autotune. Just brass, groove and sweat.



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="PsychoBoogieHoochieCoo (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/DlQuGfovDEg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div></figure>



MusicRow nailed it: "Funky, horn-punctuated Southern rock with some built-in grease."



The band describes itself as the &#8220;Coolest Dad Rock Band in America,&#8221; but that barely scratches it. Picture the swagger of Little Feat, the freak of Funkadelic and the slink of The Meters—wrapped in Jet Black Roses' Louisiana-born harmonies and storytelling.



It&#8217;s shared stages with Styx, Sammy Hagar and Collective Soul. It&#8217;s not riding genre trends. It&#8217;s playing from the gut—and it shows.



It&#8217;s 2025 is just getting started.



Lead image courtesy of Psyop

Snoop Dogg&#39;s AI-enhanced visual trip and Jet Black Roses&#39; funky anthem dropped on 4/20. One smokes, the other burns. Both hit hard.

Snoop Dogg&#39;s &#39;Last Dance&#39; Is Cannabis Cinema At Its Weirdest—And There&#39;s A Funkadelic &#39;Dad Rock&#39; Counterpart

Shares of Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration (FDA), which resulted in strong interest in potential military and defense <a href="https://www.benzinga.com/pressreleases/25/04/b44920336/tivic-health-reports-white-house-briefing-and-fda-meetings-secured-positive-interest-in-potential-">product candidates</a>.



What To Know: Tivic disclosed that it presented its therapeutic programs to senior leadership at the White House and FDA on Thursday. Discussions centered around the company's TLR5 and non-invasive cervical vagus nerve stimulation (ncVNS) programs. 



The White House meeting focused on the TLR5 program and its lead product candidate, Entolimod, which is being developed to treat acute radiation syndrome. The briefing addressed the need for better treatment options for radiation exposure and highlighted Entolimod's role in enhancing immune response through the TLR5 pathway, which is part of the body's innate immune system.



The company noted that Entolimod previously received significant development funding from various U.S. government agencies, including BARDA, NASA, the Defense Threat Reduction Agency, the Department of the Army and the Department of Defense. Tivic emphasized the potential for Entolimod to offer advantages over current treatments, such as providing gastrointestinal and hematopoietic protection from radiation in a single dose.



In a separate meeting, Tivic met with senior leadership at the FDA to discuss potential expedited regulatory pathways for both Entolimod and Entolasta, a second-generation TLR5 agonist. 



The company also presented its ncVNS program to the FDA, which is targeting a range of inflammatory, cardiac and neurologic conditions. The FDA gave favorable feedback, including potential support for breakthrough device designation upon completion of relevant clinical work.



&#8220;We deeply appreciated the opportunity to discuss the importance of our clinical pipeline in potentially protecting and healing both active and retired military personnel, first responders, as well as U.S. citizens and our allies,&#8221; said Jennifer Ernst, CEO of Tivic Health.



&#8220;While these meetings were informal in nature, we expect to continue these discussions as Entolimod and our ncVNS medical programs progress toward potential FDA approval.&#8221;



TIVC Price Action: Tivic Health shares traded as high as $13.23 on Tuesday. The stock was up 107.7% at $7.28 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro.</a>



<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png" alt="" class="wp-image-882548" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06.png 1496w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>



Read Next:



<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44930495/wall-street-rebounds-ahead-of-tesla-earnings-dow-adds-1000-points-bitcoin-hits-91000-whats-driving-markets-tuesday">Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>



Image via Shutterstock.

Shares of Tivic Health Systems, Inc. (NASDAQ: TIVC) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration (FDA), which resulted in strong interest in potential military and defense product candidates.

Tivic Health Systems Stock Is On Fire Today: What&#39;s Going On?

Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), considered a proxy for large-cap growth and tech-dense innovation, faltered considerably in 2025.



What Happened: The ETF has had year-to-date losses of 13.44%. While alarming on its own, this number conceals more profound undercurrents within its<a href="https://www.benzinga.com/etfs"> underlying makeup</a>, most notably the fortunes of &#8220;Magnificent Seven&#8221; stocks, which collectively comprise more than 40% of the QQQ.



The decline among these mega-cap growth stars has been swift and, by some accounts, historic. Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>) mirrors this group of stocks and is down over 12% for the past six months.



As investment advisory company Bespoke Investment Group recently<a href="https://www.benzinga.com/25/04/44916598/tariff-pause-fizzles-mag-7-stocks-slide-back-to-pre-pause-lows"> noted, there is more downside risk</a>.



Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44895562/3-high-risk-etfs-aggressive-retail-investors-cant-stop-buying">3 High-Risk ETFs Aggressive Retail Investors Can&#8217;t Stop Buying</a>



A convergence of global macroeconomic headwinds has helped to bring about this weakness. J.P. Morgan Asset Management <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">underscores </a>that around 75% of the suppliers to these companies are overseas, many in jurisdictions that are newly subject to fresh tariffs under new U.S. trade policy. 



Adding to the squeeze, corporate behemoths and Mag7 members such as Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) get more than half of their revenues abroad. Consequently, rising trade tensions and supply chain risks continue to be primary risk considerations for investors assessing exposure to QQQ or its underlying tech giants.



Why It Matters: A wider view presents a more complex picture. According <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">to </a>J.P. Morgan&#8217;s Stephanie Aliaga, the recent decline has not been caused by a deterioration in underlying fundamentals. 



Instead, it is a repricing of risk in the face of heightened uncertainty regarding margins, capital spending, and earnings expectations. This has resulted in significant compression in valuation. 



Importantly, the forward price-to-earnings (P/E) multiple for the Magnificent Seven has fallen from around 31x early in the year to about 22x—its lowest price since January 2023, before the then-ongoing artificial intelligence (AI) cycle of investment.



This relative discount may attract long-term investors looking for quality at a better entry point. These companies are at the core of the QQQ portfolio and leading in innovation, especially in AI and cloud computing. Their impact on the overall market, and the QQQ, is still unbroken.



However, near-term prudence is likely to be justified. Trade headwinds are not likely to subside quickly, and more volatility in mega-cap growth can be expected. But for those with the stomach for short-term dislocations, the combination of cheap valuations and continued innovation leadership presents an attractive argument for revisiting QQQ and its Mag 7 exposure.



Read Next: 



<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44933272/rnty-yieldmaxs-bold-new-real-estate-etf-that-builds-income-one-option-at-a-time">RNTY: YieldMax&#8217;s Bold New Real Estate ETF That Builds Income, One Option At A Time</a></li>
</ul>



Image: Shutterstock

In 2025, the Invesco QQQ Trust has suffered losses due to declining mega-cap tech stocks, impacted by trade tensions and supply chain risks.

Magnificent Meltdown: QQQ Tanks As Big Tech&#39;s Shine Wears Off, But There&#39;s A Silver Lining

Several analysts lowered the price forecast for Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) following the release of its first-quarter FY25 results <a href="https://www.benzinga.com/25/04/44920250/comerica-analysts-slash-their-forecasts-after-q1-earnings" target="_blank" rel="noreferrer noopener">on Monday</a>.



The company posted quarterly earnings of $1.25 per share, which beat the analyst consensus estimate of $1.15 per share and sales of $829.0 million, but missed the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus estimate of $831.34 million</a>.



Comerica sees FY25 net interest income growth of 5%-7%, average deposits decline of 2%-3%, and average loan decrease of 1%-2% full-year average, <a target="_blank" href="https://investor.comerica.com/quarterly-results" rel="noreferrer noopener">or </a>~flat point to point.



For the second quarter of FY25, the company projects average loans to be slightly lower sequentially (Q/Q) and net interest income <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to be relatively flat Q/Q</a>.



RBC Capital analyst Jon G. Arfstrom maintained an Outperform rating and lowered the <a href="https://www.benzinga.com/quote/CMA/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $75 to $65.</a>



The analyst writes that first-quarter results aligned with their expectations and those of peers. Margin expansion kept net interest income stable, and both credit trends and expenses were strong, he added.



Arfstrom says that the company&#8217;s FY25 outlook reflects softer near-term loan growth, which seems a sensible adjustment <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">amid current macro conditions</a>.



He maintained EPS estimates of $5.30 for 2025 and $5.80 for 2026.



In this environment, Arfstrom expects the bank to keep its CET1 ratio above the 10% target and resume share buybacks resuming in the second quarter.



Keefe, Bruyette &amp; Woods analyst Christopher McGratty slashed the price target from $77 to $68 while keeping an Outperform rating.



The analyst says that the company reported strong first-quarter results driven by improved PPNR and credit performance.



The revised 2025 outlook suggests roughly a 2% downside to consensus estimates, added McGratty.



Truist Securities analyst Brian Foran slashed the price forecast from $65 to $57 while keeping the Hold rating.



The analyst reduced 2025 EPS estimate by 4% to $5.10 and 2026 EPS estimate by 3% to $5.70.



The revisions reflect lower fee income and slightly softer net interest income, partially offset by reduced expenses and additional share repurchases, Foran added.



Price Action: CMA shares are up 0.79% at $51.00 at the last check Tuesday.



Read Next:



<ul>
<li><a href="https://www.benzinga.com/25/04/44916944/us-stocks-likely-to-open-higher-amid-trumps-preemptive-rate-cut-call-earnings-are-starting-to-reflect-this-uncertainty-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher Amid Trump&#8217;s Preemptive Rate Cut Call: Earnings Are Starting To Reflect This &#8216;Uncertainty,&#8217; Says Expert</a></li>
</ul>



Photo: Shutterstock

Analysts lower price forecast on Comerica (CMA) after Q1 earnings missed sales estimate but beat EPS. FY25 outlook reflects slower loan growth.

Analysts Trim Comerica Price Forecasts On Softer Outlook Despite Strong Q1

The U.S. tech sector just walked into a geopolitical buzzsaw, and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) may be <a href="https://www.benzinga.com/quote/nvda/news">the first big casualty</a>. As trade tensions ratchet up and tariff policy gets more unpredictable, AI leaders such as Nvidia are getting boxed out of China just as competitors like Huawei prepare to strike.



Wedbush Securities analyst Dan Ives isn't mincing words: "The U.S. tech industry in particular is front and center in this Category 5 storm." 



The spark? A chaotic rollout of new trade barriers, including a ban on Nvidia's H20 chip in China — a move that Ives says is "cutting U.S. tech at the knees and helping steamroll China tech ahead."



Read Also: <a href="https://www.benzinga.com/25/04/44927300/this-nvidia-backed-ai-upstart-boasts-extremely-rapid-revenue-growth-analyst-initiates-overweight">Nvidia-Backed AI Startup Boasts &#8216;Extremely Rapid Revenue Growth&#8217; &#8211; JPMorgan Initiates With Overweight</a>



In contrast, Huawei is already gearing up to ship its rival 910C AI chip — comparable to Nvidia's H100 — by early May. Chinese firms, blocked from Nvidia's offerings, are "picking up the phone and calling Huawei," according to Ives.



In short, the U.S. is losing leverage and China is gaining momentum.



The stakes are massive. 



"For the first time in 30 years, the U.S. is ahead of China when it comes to AI," Ives notes. 



But that edge could erode fast. With supply chains in disarray and CEOs unsure of the rules, even bellwethers such as Apple and Tesla may struggle to stick to product road maps.



Ives is urging policymakers to act: "This game of high-stakes poker from the White House needs to result in trade deals ASAP." Without progress, the market could "go into bunker mode,&#8221; by slashing spending, hiring and investment.



In Ives' words, "the longer this drags on, U.S. tech takes a step back… while China tech sees tailwinds."



Until then, welcome to the &#8220;economic Twilight Zone,&#8221; says Ives. 



Read Next: 



<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44917580/nvidia-ceo-jensen-huang-earns-praise-from-rival-intels-former-ceo-pat-gelsinger-run-hard-to-stay-in-the-front">Nvidia CEO Jensen Huang Earns Praise From Former Intel CEO Pat Gelsinger: &#8216;Run Hard To Stay In The Front&#8217;</a></li>
</ul>



Photo: Shutterstock

U.S. tech faces storm as trade tensions rise, with Nvidia at risk in China. Huawei gains momentum with AI chip while U.S. loses leverage, warns analyst.

US Tech In Tariff &#39;Twilight Zone&#39; Says Dan Ives: Nvidia Chip Restrictions In China, Huawei Steps Into The Void

Latest News

acf/content-feed

Get the latest Share Market Trends & News

Take Stock Of The Week Ahead

acf/beehiiv-email-capture

India Horizontal Banner Ad Unit

acf/widget-container

acf/google-ad-placement

Why is it Moving?

acf/news-list-group

Social Buzz

Exclusive: Antix CEO On Creating Hyper-Realistic Digital AI Avatars (UPDATED)

EXCLUSIVE: Worksport&#39;s March B2B Sales Soar Nearly 70%

Easter Candy Sticker Shock: Trump Tariffs And Climate Threaten to Make Your Chocolate Bunny A Luxury Item

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

EXCLUSIVE: La Rosa FY24 Revenue Jumps 119%, CEO Reiterates FY25 Topline Goal Of $100 Million

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

EXCLUSIVE: When Volatility (VIX) Peaks, Will That Be The Bottom? Watch These Signals, Says Direxion Expert

EXCLUSIVE: Traders May Be Getting The Tariff Playbook All Wrong, Here&#39;s Why

How One European Company Is Flooding America With Cannabis Seeds

Exclusive: Argent&#39;s New ETFs Are Not Chasing AI Or Meme Stocks, Here&#39;s What They&#39;re Buying Instead

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs

Exclusives

acf/carousel-news

Advertise With Us

Get all the latest Share Market trends and news to set you up for the week ahead.

India Latest News